Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H42N8O10 |
InChIKeyOSHSZIUETDVPOD-UHFFFAOYSA-N |
CAS Registry2794988-38-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 24 Dec 2022 |





